ArticleMolecular vision2015
Crosslinked chitosan-dextran sulfate nanoparticle for improved topical ocular drug delivery.
Article in Molecular vision, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Recent Advancements in Nanopharmaceuticals for Novel Drug Delivery Systems.Pharmaceutical nanotechnology · 2025Review
- Effect of naringenin based nanocomposites and pure naringenin on cumin (Physiology and molecular biology of plants : an international journal of functional plant biology · 2024Article
- The Advancement and Obstacles in Improving the Stability of Nanocarriers for Precision Drug Delivery in the Field of Nanomedicine.Current topics in medicinal chemistry · 2024Review
- Chitosan-Based Particulate Carriers: Structure, Production and Corresponding Controlled Release.Pharmaceutics · 2023Review
- Dextran Sulfate Nanocarriers: Design, Strategies and Biomedical Applications.International journal of molecular sciences · 2022Review
- Nanoscale Delivery Systems of Lutein: An Updated Review from a Pharmaceutical Perspective.Pharmaceutics · 2022Review
- Considerations for Polymers Used in Ocular Drug Delivery.Frontiers in medicine · 2021Review
- Modular Chitosan-Based Adsorbents for Tunable Uptake of Sulfate from Water.International journal of molecular sciences · 2020Article
- Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.Molecules (Basel, Switzerland) · 2020Article
- Rapid assessment of ocular drug delivery in a novel ex vivo corneal model.Scientific reports · 2020Article
- Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments.Polymers · 2020Review
- Stable Chitosan-Based Nanoparticles Using Polyphosphoric Acid or Hexametaphosphate for Tandem Ionotropic/Covalent Crosslinking and Subsequent Investigation as Novel Vehicles for Drug Delivery.Frontiers in bioengineering and biotechnology · 2020Article
- Article
- Supramolecular Carotenoid Complexes of Enhanced Solubility and Stability-The Way of Bioavailability Improvement.Molecules (Basel, Switzerland) · 2019Review
- Chitosan-Based In Situ Gels for Ocular Delivery of Therapeutics: A State-of-the-Art Review.Marine drugs · 2018Review
- Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.Drug delivery and translational research · 2016Review
- "The Good, the Bad and the Ugly" of Chitosans.Marine drugs · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine the benefits of chitosan-dextran sulfate nanoparticles (CDNs) as a topical ocular delivery system with lutein as a model drug.
methodsCDNs were developed by polyelectrolyte complexation of positively charged chitosan (CS) and negatively charged dextran sulfate (DS). 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and polyethylene glycol 400 (PEG400) were used as co-crosslinking and stabilizing agents, respectively. The influence of these on the properties of CDNs, including drug release and mucoadhesiveness, was examined. The chemical stability of lutein in CDNs (LCDNs) was also examined.
resultsTypically, LCDNs showed a spherical shape, possessing a mean size of ~400 nm with a narrow size distribution. The entrapment efficiency of lutein was in the range of 60%-76%. LCDNs possessing a positive surface charge (+46 mV) were found to be mucoadhesive. The release profile of LCDNs followed Higuchi's square root model, suggesting drug release by diffusion from the polymer matrix. Lutein in LCDNs showed increased chemical stability during storage compared to its solution form.
conclusionsThese characteristics of CDNs make them suitable for drug delivery to the ocular surface.
Indexed as
Identifiers
26604662PMC4626781What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.